Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

1.88
Delayed Data
As of 12:08pm ET
 +0.2186 / +13.17%
Today’s Change
1.23
Today|||52-Week Range
2.31
-3.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$64.1M

Company Description

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Contact Information

Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Alpharetta Georgia 30009
P:(678) 221-3343
Investor Relations:

Employees

Shareholders

Mutual fund holders7.29%
Other institutional28.25%
Individual stakeholders0.96%

Top Executives

Joseph M. PattiPresident, CEO & Executive Director
Mark P. ColonneseChief Financial Officer & Executive Vice President
John H. VernachioVice President-Preclinical Development
Anna Novotney-BarryVice President-Clinical Development
Jonas NiauraVice President-Corporate Development & Strategy